A retrospective analysis of the use of loteprednol etabonate ophthalmic suspension 0.5% following canaloplasty

A retrospective analysis of the use of loteprednol etabonate ophthalmic suspension 0.5% following canaloplasty

Mahmoud A Khaimi Dean McGee Eye Institute, Oklahoma City, OK, USA Background: While loteprednol etabonate (LE) suspension 0.5% is approved for the treatment of postoperative ocular inflammation, there have been no reported studies of its use in glaucoma patients undergoing canaloplasty.Methods: Th...

Full description

Bibliographic Details
Main Author: Khaimi MA
Format: Article
Language:English
Published: Dove Medical Press 2018-02-01
Series:Clinical Ophthalmology
Subjects:
canaloplasty
loteprednol etabonate
post-operative inflammation
glaucoma
intraocular pressure
Online Access:https://www.dovepress.com/a-retrospective-analysis-of-the-use-of-loteprednol-etabonate-ophthalmi-peer-reviewed-article-OPTH

Internet

https://www.dovepress.com/a-retrospective-analysis-of-the-use-of-loteprednol-etabonate-ophthalmi-peer-reviewed-article-OPTH

Similar Items